Arcutis shares traded higher on Monday after Health Canada approved its Zoryve cream for the treatment of mild to moderate ...

Phase 3 trial results show roflumilast cream 0.05% to be a safe and effective treatment for children with atopic dermatitis.

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Many people still rely on baby products to keep their skin soft, supple, and flawless—just like a baby’s. But did you even ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Like every industry, skincare has a few big-name players. A-listers like retinol and hyaluronic acid monopolize attention and ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a ...

AlphaQuest LLC lessened its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 83.3% in the ...